

RHINOMED

ANNUAL GENERAL MEETING – 29 NOVEMBER 2019

ASX:RNO

OTCQB:RHNMF

IMPORTANT NOTICE AND DISCLAIMER

You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the following terms and conditions, including any modifications to them. The information in this document has been prepared in good faith by Rhinomed Limited ACN 107 903 159 (Rhinomed). Rhinomed has prepared this document based on information available to it to date. No representation or warranty, express or implied, is made by any person as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this document or any other information provided by Rhinomed, its respective affiliates or related bodies corporate (as that term is defined in the Corporations Act 2001 (Cth) (Corporations Act) or their respective officers, employees, directors, partners, representatives, agents, consultants or advisers (each a Limited Party and together, the Limited Parties) or any other person otherwise provides to you. To the maximum extent permitted by law, neither Rhinomed, their respective affiliates or related bodies corporate accepts any liability including, without limitation, any liability arising from fault, negligence or omission on the part of any person, for any loss, costs or damage arising from the use of this document or its contents or otherwise arising in connection with it. This includes for any indirect, incidental, consequential, special or economic loss or damage (including without limitation, any loss of profit or anticipated profit, fines or penalties, loss of business, or anticipated savings, loss of use, business interruption or loss of goodwill, bargain or opportunities). This document has not been lodged with ASIC, or otherwise.

Summary information

This document contains summary information about Rhinomed and its activities which is current as at the date of this document, unless otherwise indicated. The information in this document remains subject to change without notice, and Rhinomed is not responsible for updating, nor does it undertake to update, it. This presentation should be read in conjunction with Rhinomed's periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at https://www.rhinomed.global/investor-information/ or www.asx.com.au.

Risk Factors

An investment in Rhinomed securities is subject to known and unknown risks, a number of which are beyond the control of Rhinomed. Rhinomed does not guarantee any particular rate of return or the performance, nor does it guarantee the repayment of capital from Rhinomed or any particular tax treatment. When making their investment decision prospective investors should make their own enquiries and investigations regarding all information in this document, including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Rhinomed and the impact that different future outcomes may have on Rhinomed.

No Liability

The information contained in this document has been prepared in good faith by Rhinomed however no guarantee representation or warranty expressed or implied is or will be made by any person (including Rhinomed and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document.

To the maximum extent permitted by law, Rhinomed and its affiliates and their directors, officers employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice. No responsibility or liability is assumed by Rhinomed or any of its affiliates for updating any information in this document or to inform any recipient of any new or more accurate information or any errors or mis-descriptions of which Rhinomed and any of its affiliates or advisers may become aware.

Forward Looking statements

This document contains certain forward-looking statements, relating to Rhinomed Limited's (Rhinomed) business which can be identified by the use of forward looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of the company's technologies and products.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy any specific health authority and other health authorities requirements regarding any one or more product or technology nor can there any assurance that such products or technologies will be approved by any health authorities for sale in any markets or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialization of the technology could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, technology, financial result, and business prospects.

Should one of more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Rhinomed Is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Not Financial Product Advice

This document does not it constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in Rhinomed is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

RHINOMED

CORPORATE OVERVIEW



Key Metrics	
Market Cap	~AU$35m
Current Stock price	A$0.20
Shares on issue	169m
Top 20 Investors	71%

Board and Management	
Mr Ron Dewhurst	Chairman
Mr Michael Johnson	CEO and Managing Director
Mr Brent Scrimshaw	Non Executive Director
Dr Eric Knight	Non Executive Director
Mr Sean Slattery	CFO

Top Investors	
Mr Whitney George (US)	25%
Dr John McBain (Aust)	9%
Mr Paul Stephens (US)	6%
Perennial Funds	5.37%

RHINOMED LIMITED

POSITIONED FOR GROWTH

Rhinomed is experiencing rapid growth:

- Targeting large addressable markets in sport, sleep, respiration, allergies, congestion and anxiety
- Product stocked in approx. 12k+ stores globally

Rhinomed is experiencing rapid sales growth from enhanced consumer awareness of its products:

- Revenues have tripled over the last 4 years, are up 50% YoY to $3.2m and forecast to continue growing to $5.5m in FY20
- Product range on sale jumping from three to eight in 2020

Significant scope for earnings enhancement as revenues grow:

- 70%+ gross margins
- Low fixed cost base circa $5m pa.
- R&D costs incurred and regulatory registrations granted

Company recently raised $6m via share placement. Funds will support growth in sales, product roll outs and working capital

STAGE SET FOR TRANSFORMATIONAL YEAR

NEW PRODUCTS, NEW STORES, REVENUE GROWTH



- Revenue growth to accelerate in FY20 and beyond driven by organic growth in current products, new product launches and significant store growth.





RHINOMED LIMITED

DELIVERING A GLOBAL STRATEGY BUILT UPON FOUR PILLARS

REVOLUTIONARY DRUG DELIVERY PLATFORM	Validated technology -Intranasal drug delivery platform	Protected by 60 patents, 57 design patents, trademarks	Applications across multi-billion $ global markets	PROTECTED
COMMERCIALISED PRODUCTS	Successful US FDA, CE Mark, Australian TGA regulatory registration	Three proprietary products now in market	Five new products to be launched in late 2019 and 2020	PIPELINE
GLOBAL DISTRIBUTION NETWORK	Global ecommerce platform delivering 30% of revenues	Approx. 10,000 pharmacies in USA, 2,000 in ROW.	Pipeline of 30,000+ stores in USA and ROW	PREMIUM
PROVEN LICENSING MODEL	Licensing opportunities in global OTC consumer health markets	Licensing opportunities in multi-billion $ global Rx drug markets	First licensing deal delivered in $18bn US CBD and medical cannabis market	PROVEN

PRODUCTS, DISTRIBUTION AND LICENSING

BUILDING CATEGORY LEADING BRANDS

DELIVERING SALES AND PRODUCT SUCCESS

2014

2016

2019

2019

TURBINE SPORT BREATHING TECHNOLOGY

FIRST PRODUCT SUCCESSFULLY COMMERCIALISED

- Niche position in global sport, yoga, aerobic exercise markets
- Online Distribution and select US stores
- 70% Gross Margins
- Adopted by athletes in running, cycling, aerobic activity – used in NYC marathon, Tour de France, Rio Olympics, etc.
- Class 1 registration with US FDA, CE Mark, Australian TGA, Canada Health and Taiwanese FDA



MUTE - FASTEST GROWING BRAND IN US NASAL STRIP MARKET

CONSUMER HEALTH PRODUCT FOR GLOBAL SLEEP MARKET

- Now in 12,000+ stores globally
- Approx 10,000 in USA, 2,000 ROW
- 70% Gross Margins
- Delivered 95% of FY19 revenues
- Brought business back in house in Australia and seen strong growth
- Class 1 registration with US FDA, CE Mark, Australian TGA, Canada Health and Taiwanese FDA
- Companion therapy for Obstructive Sleep Apnea market – CPAP and Oral Advancement Therapies



PRONTO SLEEP

DRIVING GROWTH IN GLOBAL OTC SLEEP CATEGORY

- On shelf in ~1,000 Walgreens stores from July 2019
- Seeking to replicate Mute distribution of 12,000 stores globally and online
- 70% Gross margins
- FDA, CE Mark and TGA Class 1 registration May 2019
- Proprietary essential oil formulation to aid with sleep
- Unique rechargeable pod delivering up to 10 nights of better sleep
- Strengthening Rhinomed presence in global Sleep category

PRONTO CLEAR

BRINGING INNOVATION TO GLOBAL DECONGESTION MARKET

- Released late 2019
- Seeking to replicate Mute distribution of 12,000 stores globally 2020/21
- 70% Gross margins
- FDA, CE Mark and TGA Class 1 registration May 2019
- Proprietary nasal decongestion essential oil formulation
- Unique rechargeable pod delivering up to 10 nights of nasal relief
- Growing Rhinomed's presence in global nasal congestion market

RHINOMED HAS A PIPELINE OF NOVEL TECHNOLOGY

TARGETING CONSUMER NEEDS IN HIGH GROWTH CATEGORIES

- Development of solutions where the benefits of Rhinomed's nasal drug delivery and stenting technology deliver value to:
  - Retail partners
  - Consumers,
  - Patients and clinicians
- Targeting multi billion global markets

SLEEP



ANXIETY

NASAL INFLAMATION

NAUSEA

ROLL OUT IN 2020 OF A FAMILY OF BRANDED SLEEP SOLUTIONS

THAT USE CBD AS A CATALYST FOR GROWTH

- Extension of Pronto range featuring new formulations and the inclusion of CBD
- Targeting clear unmet needs in the US$79 billion* global sleep aids market
- Building a highly valuable and strategic global franchise in OTC Consumer Health sleep solutions

* Global Sleep Aids Market , Allied Market Research, October 2019

LEVERAGING ONE OF RHINOMED'S CORE STRENGTHS

PREMIUM GLOBAL ONLINE AND RETAIL DISTRIBUTION



- Presence in 10,000 stores US, 2000 stores ROW
- Premium retail outlets:
  - Online - Amazon USA, UK and Australia
  - Drug Store/Pharmacy – Walgreens/ CVS/ RiteAid (USA), Boots (UK)
- Targeting 30,000+ stores in USA and ROW by end 2021
  - Expansion in Drug store/Pharmacy
  - Grocery
  - EDLP + Mass
  - Online – Hong Kong / China

McKESSON Empowering Healthcare · Sigma Healthcare · symbion · Kroger · RITE AID · Boots · AmerisourceBergen · CVS/pharmacy · LONDON DRUGS · amazon · Walgreens · BED BATH & BEYOND Beyond any store of its kind · FredMeyer · Harrods

COMPELLING TECHNOLOGY PIPELINE

DELIVERING VALUE OVER THE NEAR AND LONG TERM

- Continuing to grow through development of in house portfolio of branded products
- Execute licensing deals for product in pipeline

GLOBAL MARKETS	TECHNOLOGY	IN MARKET	PIPELINE			
SPORT	Stent	Turbine				
SNORING		Mute	***CY20***	CY21	LICENSING OPPORTUNITIES	
SLEEP	Airstream Platform	Pronto Sleep	Pronto Sleep Plus - CBD		Obstructive Sleep Apnea – Medical Cannabis	INSOMNIA
			Pronto Sleep Performance			
COUGH, COLD CONGESTION		Pronto Clear	Pronto Allergy Relief	Pronto Allergy Relief - CBD	Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)	COPD
NAUSEA				Pronto Nausea Relief - CBD		
PAIN					Pronto Migraine Relief	MIGRAINE
ANXIETY			Pronto Relax - CBD	Pronto Focus - CBD	PTSD	CNS DISORDERS

FIRST LICENSING DEAL COMPLETE

$18 BILLION US CBD AND MEDICAL CANNABIS MARKET



Validating both technology and licensing model

- 12 year licensing deal
- Exclusive to the USA
- Columbia Care is a leading player in the US CBD and medical cannabis market
- US CBD market expected to reach US$18 billion by 2025
- Cost plus double digit royalty rate
- PLUS Double digit profit share depending on distribution channel
- Includes both CBD and medical cannabis applications

14% of Americans say they use CBD products
- 40% for pain
- 20% for anxiety
- 11% for sleep

Gallup June 19-July 12 2019

LICENSING STRATEGY

PLATFORM APPEAL ACROSS BOTH OTC AND RX APPLICATIONS

- Rhinomed platform provides the potential for a truly unique delivery profile:
    - Fast acting like a spray
    - Sustained release like a patch

Nasal drug delivery offers significant benefits over other delivery modes	Rapid absorption - higher bioavailability
	Fast onset therapeutic mode of action
	Avoidance of first pass through the liver
	Titratable delivery
	Long release
	Controlled/Sustained release
	Ability to micro low dose

LICENSING STRATEGY

CHANGING THE DRUG DELIVERY PARADIGM

1. Rhinomed has established acceptance and adoption of the technology in Global OTC markets as a Class 1 device.
2. Business development program will target those seeking:
    1. An innovative, non-oral, or non-injected delivery platform for their proprietary CNS, systemic, or topical nasal compounds.
    2. To re-evaluate promising compounds that experienced clinical development challenges due to insufficient oral bioavailability, first-pass metabolism, or speed of onset.
    3. To find new or improved uses for existing compounds.

CBD - US$18 bn

Migraine US$7.8 bn

Hormone US$4.2 bn

Nicotine replacement US$21.8 bn

Allergic Rhinitis US$7.3 bn

Vaccines

Pain

CNS disorders

Endocrine and metabolic disorders

Respiratory disorders

OUTLOOK

KEY CATALYSTS

- 4 new Products to be released before December 2020
- First CBD products to be launched in 2H FY20
    - In US via partner Columbia Care with dispensaries throughout the USA
    - ROW via existing distribution channels

Expanding distribution

- Targeting 30,000+ stores in USA and ROW inside next 2 years
- Online (Asia)

- Potential Licensing transactions for platform
    - Inbound interest and potential for further transactions
- Quarterly updates on Revenues/Stores
    - Targeting minimum revenue growth of 50% into FY20
    - 2020 product launches underpin significant growth in FY21

APPENDIX A

A NEW APPROACH TO NASAL DRUG DELIVERY

INTRANASAL DRUG ELUTING STENT

- Potential to drive a paradigm shift in drug delivery – combining rapid delivery profile of a spray with long release profile of a patch.
- Three key modalities:
    - Stenting
    - Stenting + Volatile/vapor inhalation delivery
    - Stenting + nasal mucosal delivery
- Strategic appeal to new drug developers, specialty pharma and generic pharma seeking novel delivery solutions

- Tailored controlled or sustained release modalities
- Variable dose controlled – micro/low dosing
- Long release (overnight) and/or rapid onset
- Compelling safety profile - instant removal in case of adverse effect
- Multiple deliverable modes and dosage options: transdermal, Inhalation trans-mucosal
- Gel, Powder, Liquid or volatile vapor formulation applications



RHINOMED NASAL STENT

IN-SITU NASAL DRUG DELIVERY PLATFORM

A platform delivering stenting, vapour release, drug release, sensor and monitoring capabilities

Two form factors already in market

Independent arm capable of holding medicament formulations, sensors, etc

Proprietary ratcheting stent delivering individualised fit, greater airflow and direct contact with internal nasal dermal and or mucosa surface

Dilates from the back of the nose minimising pressure on the septum and delivering comfort and fit

Manufactured from medical grade polymer (latex and BPA free) capable of releasing medicaments

Mute™ dilation technology providing individual fit and naturally unobstructed breathing

Recharging Pod provides both essential oil recharge and secure storage

Air-Stream™ delivery system places proprietary vapor formulation into nasal air stream without skin contact

Proprietary and pure essential oil blends formulated for optimal effectiveness

Patented Recharging system – recharges in minutes for up to 8 hours of use



CONTACT

Michael Johnson - CEO

mjohnson@rhinomed.global